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Abstract
Hemolysis is an unintended sequel of temporary or permanent intracardiac devices.
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However, limited data exist on the characteristics and treatment of hemolysis in
patients with cardiac prostheses. This entity, albeit uncommon, often poses signifi-
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cant diagnostic and management challenges to the clinical cardiologist. In this article,
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and management of cardiac prosthesis-related hemolysis.

we aim to provide a contemporary overview of the incidence, mechanisms, diagnosis,
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1 | I N T RO D UC T I O N

three major criteria are present: (a) unexplained anemia, and
(b) signs of accelerated right blood cells (RBCs) production in the

Cardiac prosthesis-related hemolytic anemia (CPHA) is a well

bone marrow (eg, high reticulocyte count), and (c) signs of RBCs

described but likely an under-recognized phenomenon. This poten-

destruction (eg, elevated unconjugated bilirubin, lactate dehydro-

tially life-threatening complication was first described in the 1950s to

genase [LDH], low haptoglobin). The term “sub-clinical hemolysis”

1960s in patients undergoing valve replacement with early generation

is used to describe patients who meet the latter two criteria but

surgical prostheses.1,2 The incidence of clinically evident hemolysis
after surgical valve replacement has since declined due to the
improved valve design and surgical implantation techniques.3,4 However, interest in CPHA has been recently renewed given the increasing number of studies reporting various rates of clinical and subclinical
CPHA with mechanical circulatory support devices and transcatheter
valvular interventions.5-7 Nonetheless, the management of CPHA is

do not have anemia. In these patients, the bone marrow adequately compensate for the hemolysis, maintaining normal hemoglobin. Prosthesis-related hemolytic anemia can then be assumed
if new hemolysis is diagnosed in patients with cardiac prostheses,
and/or mechanical assist devices in the absence of other causes of
hemolysis.

often challenging due to its atypical presentation, lack of standardized
definitions/classifications, and due to the dearth of outcomes data on
its various treatment strategies. We sought to provide a contemporary overview of the current literature on the incidence, mechanisms,

3 | I N C I D E NC E A N D E T I O L O G Y O F
C A R D I A C P R O S T H E S I S - RE L A T E D
HE MO LY SIS

and management strategies of hemolytic anemia associated with various cardiac prostheses.

The incidence of hemolysis in patients with cardiac prostheses
varies widely according to the device type and its indwelling

2 | D E F I NI T I O N O F H E M O L Y T I C A N E M I A

time. Mechanical damage to the RBCs due to increased shear
stress is the most widely accepted etiology of CPHA. However,

There is no single specific definition of hemolytic anemia. How-

causes of this increased shear stress are device- and disease-

ever, the diagnosis of hemolytic anemia is usually established if

specific.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
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3.1 | Hemolysis after open valve surgery
Hemolytic anemia was a common complication of old generation val-

3.2 | Hemolysis after transcatheter valve
replacement

ves, occurring in up to 15% of surgical valves in the 1960s to

The incidence of hemolysis after transcatheter aortic valve replace-

1970s.8,9 However, this incidence decreased to <1% with modern

ment (TAVR) is unknown because routine surveys are not performed

valve designs. In a study of 301 patients who underwent On-X

in these patients. Although clinical hemolysis is not commonly seen,

mechanical valve replacement, clinical hemolysis at long-term

subclinical hemolysis following TAVR may not be uncommon.17,28 In a

occurred in 0% and 0.2% of patients who had aortic and mitral valve

study of 122 patients who had TAVR with balloon-expandable valves,

replacement, respectively. Several other studies confirmed the rarity

subclinical hemolysis occurred in 15%. The strongest predictor of

of clinical hemolysis after valve replacement with contemporary pros-

hemolysis was patient-prosthesis mismatch, rather than the degree of

3

Nonetheless, subclinical hemolysis is not uncommon,

PVL.7 This intriguing finding, albeit requires confirmation in additional

occurring in 18% to 51% and in 5% to 10% of contemporary mechani-

studies, suggests that transcatheter (vs surgical) prostheses may be

cal tissue prostheses, respectively.12,13 The main mechanism of hemo-

associated with less hemolysis given their lower reported incidence of

4,10,11

theses.

lysis after surgical valve replacement is paravalvular leak (PVL), which
may result from suture dehiscence due to heavy annular calcifications,
endocarditis, chronic steroids, or suboptimal surgical techniques.14-17
Other less common etiologies of hemolysis related to surgical pros-

patient-prosthesis mismatch.29 In another study of 64 TAVR patients,
37.5% had evidence of subclinical hemolysis 6 months after the procedure.30 Moderate to severe PVL and bicuspid valve morphology
independently predicted hemolysis (Figure 1A,B), and hemolysis was
associated with a 4-fold increase in hospital readmissions at 1 year.

18-21

theses are listed in Table 1.

Hemolysis also complicates a small percentage (<1%) of mitral
valve repair and annular ring placement surgeries.22-25 Although ring
dehiscence appears to be the main mechanism of CPAH in this
group, other reported mechanisms include: protruding of the paravalvular suture material, “whiplash motion” of residual free-floating
chordae in hyperkinetic ventricles, and small but turbulent eccentric
residual regurgitation jet (Table 1). In this large series, valve replacement led to the resolution of hemolysis in the vast majority of
cases.26,27

Of note, 21% of patients had evidence of sub-clinical hemolysis
before TAVR; supporting the notion that severe native aortic stenosis
can lead to hemolysis due to flow acceleration across the stenotic
valve.31,32 Other TAVR-specific mechanisms of CPAH are related to
the remaining native leaflets and their potential impact on red cell
shear stress (Table 1).7
The field of transcatheter mitral valve replacement (TMVR) is rapidly evolving.33 However, given the small number of TMVRs performed worldwide, data on TMVR associated hemolysis are limited. In
the early feasibly trial of the Tendyne valve (Abbott, Roseville, Minnesota), only 1 of 30 patient (3.3%) developed severe hemolysis.34 The

TABLE 1

Mechanisms of cardiac prosthesis-related hemolysis

Cardiac device

Mechanisms of hemolysis

Surgical aortic and mitral
valve replacement

PVL, SVD, PPM, endocarditis, leaflet
thrombosis

Surgical mitral valve repair

Transcatheter aortic valve
replacement

Ring dehiscence, residual eccentric or
para-ring regurgitation, protrusion
of suture material, free-floating
chordae in hyperdynamic left
ventricle

main mechanism of hemolysis after TMVR is PVL due to incomplete
sealing, device undersizing, or progressive left ventricular remodeling
(Figure 1C,D). Cases of severe clinical hemolysis have also been
reported

following

transcatheter

mitral

valve

in

valve/ring

implantation.35

3.3 | Hemolysis with left ventricular assist devices
The reported incidence of hemolysis with the HeartMate II (HMII;

PVL, PPM, increased red cell shear
stress in the sinuses due to residual
native valve fissuring and
balloon-induced endothelial
denudation

Thoratec, Pleasanton, California) is approximately 13% to 18%.5,36,37

Transcatheter mitral valve
replacement

PVL

toroidal-flow LVAD has shown negligible rates of hemolysis in pre-

Surgical left ventricular
assist devices

Pump thrombosis,
transfusion-associated hemolysis,
cannula kinks or malposition,
dehydration ! LV under filling !
increased inlet velocity

However, early experience with the third generation magnetically levitated left ventricular assist devices (LVAD) (HeartMate III) revealed
very low (<1%) rates of hemolysis.38,39 Similarly, the novel TORVAD
clinical testing.40 A unique aspect of hemolysis in LVAD patients is its
strong relationship with thrombotic complications. Local thrombosis
increases shear stress and leads to local destruction of the red cells.41
However, other mechanisms may be implicated such as increased inlet
velocities due to dehydration and under-filling of the left ventricle,

Percutaneous left
ventricular assist devices

Pump-related shear stress, device
malpositioning, device malfunction

transfusion-associated hemolysis, and cannula kinks or malposition

Intracardiac shunt closure

Incomplete closure (peri-device leak)

hemoglobin levels in LVAD patients is viewed as a possible early can-

Abbreviations: LV; left ventricle; PVL, paravalvular leak; PPM;
patient-prosthesis mismatch; SVD, structural heart deterioration.

(Table 1).41-43 In current practice, an increase in LDH and plasma free
nula thrombosis.5 Clinical hemolysis in surgical LVAD patients is associated with significant morbidity and mortality.44-46
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F I G U R E 1 Severe hemolysis due
to paravalvular leak after
transcatheter aortic and mitral valve
replacement. A,B, Paravalvular leak
after transcatheter aortic valve
replacement before and after
percutaneous closure. C,D,
Paravalvular leak after TMVR before
and after a second procedure to
reposition the mitral prosthesis. AV,
aortic valve; LA, left atrium; LV, left
ventricle; MV, mitral valve; arrows
annotate the location of the
paravalvular leak

Mild hemolysis occurs in 10% to 30% of patients who receive
short-term percutaneous LVAD support with the Impella device

placement.51-53 To the best of our knowledge, no cases of clinical
hemolysis due to intra-aortic balloon pumps have been reported.

(Abiomed Inc., Danvers, Massachusetts).47-49 However, the incidence
increases to 60% with device indwelling times >6 hours.6 In a study of
patients undergoing veno-arterial extracorporeal membrane oxygena-

3.4 | Hemolysis after transcatheter shunt closure

tion, concomitant Impella use was associated with higher incidence of

New hemolysis requiring blood transfusion occurred in 1% to 2% of

hemolysis (76% vs 33%, P = .004).50 Clinically significant hemolysis

patients undergoing percutaneous PVL closure in two large registries

may also occur unexpectedly due to device malfunction or improper

in the United Kingdom and the United States, likely due to incomplete

F I G U R E 2 Redo surgery for
severe hemolysis following failed
percutaneous paravalvular leak
closure attempt. A, Amplatzer
vascular plug in place, but residual
leak is present (L). B, Removal of the
Amplatzer vascular plug followed by
patch repair of the leak. MV, mitral
valve, arrows annotate the location of
the paravalvular leak
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obliteration of the PVL (Figure 2).28,54 Higher profile devices (eg, ven-

deficiency. (c) LDH: this enzyme catalyzes the conversion of lactate

tricular septal occluders) are more associated with more hemolysis

into pyruvic acid, and its iso-enzymes LDH-1 and 2 are therefore

than the lower profile Amplatzer vascular plugs.55,56 Severe hemolysis

increased in hemolysis. Although non-specific, an elevated LDH

has also been reported following percutaneous closure of septal

>2.5-folds strongly suggests hemolysis. Temporal trends in LDH are

defects and peri-MitraClip regurgitation mostly due to residual peri-

also useful in assessing treatment success in patients with PVL and

device shunt.57-63

LVAD dysfunction. (d) Haptoglobin: this scavenger binds free circulating hemoglobin released with RBC turnover, and it hence becomes
diminished or undetectable in significant hemolysis. A haptoglobin

4 | CLINICAL PRESENTATION AND
DIAGNOSTIC APPROACHES

level < 25 mg/dL provides an 87% probability of having hemolysis.65
A combination of haptoglobin <25 mg/dL and elevated LDH increases

The recognition of hemolytic anemia in patients with classic presentations is straightforward. However, CPHA commonly presents with
ambiguous symptoms, and insidious onset posing highlighting the

the predictive value to >90%. However, haptoglobin is an acute phase
reactant and its level can hence be normal or elevated in systemic
inflammation or acute infection. (e) Bilirubin: indirect bilirubin is a

need for a high index of suspicion. In a study of 381 patients who

product of hemoglobin catabolism, and its levels are thus increased in

were referred for treatment of mitral PVL (of whom 40% had hemoly-

hemolysis. Although severely elevated unconjugated bilirubin can

sis), the mean time from index valve replacement to referral was 85.1

occur with acute massive hemolysis, levels >4 mg/dL in non-acute

64

± 115.6 months.

Hence, in patients with cardiac prostheses who

have unexplained anemia, a systematic step-wise approach to

hemolysis typically indicate a concomitant liver pathology impairing
the conjugation of bilirubin or its hepatic uptake.
Additional markers of hemolysis can be used in certain

exclude/diagnose CPHA is warranted (Figure 3):

populations. For example, plasma free hemoglobin (pFH) is usually
indicative of intra-vascular hemolysis. This marker is useful in early

4.1 | Laboratory confirmation of hemolysis

detection of hemolysis in patients with LVADs. In the Interagency for

Initial testing should include: complete blood count with peripheral

Mechanically Assisted Circulatory Support registry, hemolysis is diag-

blood smear examination, reticulocyte count, LDH, bilirubin, and hap-

nosed when pFH exceeds 40 mg/dL.46 The utility of pFH in diagnos-

toglobin levels. The normal values, accuracy, and pitfalls of these tests

ing and monitoring hemolysis in patients with pLVAD and in those

are summarized in Table 1.

with PVL has also been suggested in several studies.49,66 Indeed, pFH
(eg,

was superior to LDH in detecting hemolysis in patients with cardio-

Schistocytes) are common in “mechanical” hemolytic anemia. These

genic shock treated with the Impella micro-axial pump.49 However,

fragments, however, are not specific to CPHA (Table 1). (b) Reticulo-

pFH is not widely used in this setting due to the dearth of supportive

cytes: an elevated reticulocyte count is a typical feature of hemolysis.

data and the frequent need to send out to a reference lab. Other tests

However, reticulocytes can be elevated in other causes of accelerated

indirect/less specific markers of hemolysis (mean cell volume, hemo-

red cells production (Table 1). In addition, normal or low reticulocyte

siderinuria, hemoglobin A1C, aspartate aminotransferase, etc.) may

counts do not preclude hemolysis. A blunted bone marrow response

aid in establishing or excluding the diagnosis in equivocal cases

can be seen with myelodysplasia, alcoholism, or iron and folate

(Table 2).

(a)

Blood

smear

examination:

F I G U R E 3 An algorithmic
approach to a patient with suspected
cardiac prosthesis-related hemolysis.
CTA; computed tomography
angiogram; LDH, lactate
dehydrogenase; LVAD, left
ventricular assist device; OAC, oral
anticoagulation; TEE, transesophageal
echocardiography; TTE, transthoracic
echocardiography

erythrocyte

fragments
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TABLE 2

Markers of hemolysis

Type

Test

Findings in
hemolysis

Normal values

Characteristics/pitfalls

Direct

Haptoglobin

<25 mg/dL

0.5-3.2 g/L

Most specific
" = Acute phase reactant, nephrotic syndrome, wide range of
normal values
#Trauma, congenital ahaptoglobinemia, cirrhosis

Lactate dehydrogenase

>460 μ/L

230-460 μ/L

Non-specific but LDH + # Haptoglobin>90% specific for
hemolysis
Other sources of LDH increase liver, myocardial, or muscle
injury

Indirect

Indirect bilirubin

>2 mg/dL

0.3-1.6 mg/dL

Non-specific

Aspartate aminotransferase

>40 μ/L

10-40 μ/L

Non-specific

Cell deformities on
peripheral smear,
“eg, schistocytes”

>0.5%

Absent

Non-specific, also seen in DIC, thrombotic microangiopathies,
spherocytes, elliptocytes, and sickle cells can be seen

Reticulocyte count

>2%

<2%

" With bleeding and erythropoietin use

Mean cell volume

>96 femtoliters

80-96 femtoliters

" Due to reticulocytosis

Hemosiderinuria

Brown-color urine

Absent

More characteristics of acute and marked hemolysis, which is
uncommon with cardiac etiologies of hemolysis

Hemoglobin A1C

Unexpectedly low

≤5.6

Limited time for red blood cell glycation

Plasma free Hgb

>40 mg/dL

<5 mg/dL

Not widely available (reference labs)

# with myelodysplasia, alcohol, B12/folate/iron deficiency

Abbreviations: Hgb, hemoglobin; DIC, disseminated intravascular coagulation; LDH, lactate dehydrogenase.

4.2 | Establishing the relationship between cardiac
prostheses and hemolysis
Once the hemolysis diagnosis is confirmed, establishing its relationship with cardiac prostheses is essential to guide therapy. Although
this can be challenging due to the absence of a specific test for CPHA,
the following steps may be helpful in elucidating the etiology of
hemolysis.
1. Excluding common causes of hemolysis: infection and drugs are
frequent causes of hemolysis. Discontinuation of the potential
offenders (eg, new antibiotics), and treating underlying infections may
resolve the hemolysis. Autoimmune hemolytic anemia should also

occluder devices (eg, residual leak). Although transthoracic echocardiography can often identify the site and mechanism of prosthesis dysfunction,

transesophageal

echo

is usually

necessary.

Cardiac

computed tomography might also be useful in confirming the diagnosis and guiding treatment of PVL, peri-occluder residual shunting, and
LVAD outflow graft kinks.17,42
4. Timing of presentation: Severe anemia after LVAD insertion or
valve replacement should raise suspicion of a causal relationship
between the cardiac prosthesis and hemolysis in the absence of
bleeding or infection. Nonetheless, CPHA can often be insidious and
may not be detected clinically until later stages.64

always be excluded with a direct antiglobulin test before confirming
the diagnosis of CPHA.
2. Identifying specific laboratory clues: certain laboratory findings

5 | MANAGEMENT OF CARDIAC
PRO STHE SI S-REL AT ED HE MOL Y SIS

may suggest a specific etiology for the hemolysis. For example, the
presence of spherocytes and/or a positive direct antiglobulin test sug-

The optimal treatment strategy of cardiac prosthesis-related hemoly-

gest an immune-mediated mechanism, while the abundance of

sis is determined by the degree of hemolysis, clinical symptoms, sever-

schistocytes indicates mechanical disruption of the red cells. Hence,

ity of prosthetic dysfunction, and the predicted risk and success of

the latter pattern is more likely to be observed in patients with CPHA,

surgical or percutaneous interventions.

although it can also be seen with thrombotic thrombocytopenic purpura or hemolytic uremic syndrome.
3. Imaging the cardiac prosthesis: echocardiography allows

5.1 | Medical therapy

detailed evaluation of prosthetic valve (transvalvular velocity, leaflet

Medical therapy with close follow-up is appropriate for patients with

function, PVL, etc.), LVADs (position and integrity/kinks of the

mild hemolysis that is not significantly interfering with the quality

cannula/pump, function of aortic valve, etc.), and intra-cardiac shunt

of life.
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• Folic acid: Folate deficiency is common in chronic hemolysis due to

percentage will experience worsening of hemolysis often requiring

the increased consumption from accelerated erythropoiesis.67 In

percutaneous or surgical device retrieval.81 Surgical PVL correction

persistent hemolysis, prophylactic oral folic acid supplementation

has been shown to be a more effective method in treating severe

is recommended to avoid substantial folate deficiency.

hemolysis than percutaneous repair.82 In one study, persistence of or

• Iron supplementation and blood transfusion: Oral ± intravenous

worsening hemolysis was responsible for 50% of crossovers to sur-

iron supplements may be sufficient to treat stable degrees of

gery in patients initially treated with transcatheter techniques.64 How-

hemolysis. However, blood transfusion is often needed is severe

ever, redo surgery is associated with significant morbidity and

hemolysis until mechanical corrective measures are undertaken.

mortality, and the choice of transcatheter or surgical intervention

• Beta-blocker: Beta-blockers can reduce shear forces in patients

requires a collaborative interdisciplinary approach weighting the risks

with PVL-related hemolysis reducing blood pressure and heart rate.
Oral beta-blockers led to significant improvement in hemolytic
anemia in several retrospective series.68-70

and potential success of each procedure.78
Refractory LVAD-related hemolysis: Intensification of antithrombotic therapy is able to improve or resolve hemolysis in the

• Pentoxifylline: Pentoxifylline improves blood viscosity and erythro-

majority of LVAD patients. However, persistent hemolysis despite

cyte deformability. The use of pentoxifylline may subside mild

maximally tolerated anticoagulation is associated with a substantial

hemolysis in patients with LVAD or mechanical valves.71,72 In a

increase in the risk of stroke and death.5,77 Hence, pump exchange

small randomized trial of 40 patients with CPHA, hemolysis indices

through various surgical techniques (subxiphoid ± thoracotomy or

improved in 60% of patients on pentoxifylline compared to 5% of

redo sternotomy) should be considered early in these patients.41

73

patients in the placebo group.

Occluder devices-induced hemolysis: Severe hemolysis that devel-

• Erythropoietin: This recombinant hormone has been shown to

oped or worsened after transcathter shunt closure is often due to the

eliminate the need for transfusion in selected patients with pros-

residual peri-device shunt. Those residual shunts can be often amelio-

hemolysis.74,75

erythropoietin

rated with additional occluder devices, and/or intra-device coil

administration to treat LVAD-related hemolysis was associated

deployment within the Nitinol cage of the occluder.79,83 However,

with higher odds of pump thrombosis (hazard ratio 2.35; 95% con-

replacement of the involved prosthesis with a different device or con-

fidence interval: 1.38-4.00; P = .002), and mortality (hazard ratio

version to surgical repair is often required.

thetic

valve-related

However,

1.62; 95% confidence interval: 1.12-2.33; P = .01).76
• Anticoagulation: Intensification of antithrombotic therapy is the
first recommended step in the management of LVAD associated

6 | SUMMARY

41,77

hemolysis that is believed to be due to thrombosis.

CPHA is an uncommon but important source of morbidity and mortality in patients undergoing valve surgery, transcatheter structural heart

5.2 | Invasive management
Invasive treatment is reserved for patients with severe symptomatic
hemolysis despite maximal medical therapy. The specific invasive
treatment differs according to the implicated cardiac prosthesis and

interventions, and mechanical circulatory support device implantations. Knowledge of the incidence, etiologies, and the various treatment strategies is key for effective management of this rare but
potentially life-threatening entity.

the underlying mechanism of hemolysis.
Paravalvular leak repair: The efficacy of transcatheter PVL repair

CONFLIC T OF INT ER E ST

in reducing heart failure symptoms and long-term mortality has been
demonstrated in multiple studies.28,64,78 However, the literature on

The authors declare no potential conflict of interests.

the role of transcatheter PVL correction in resolving hemolysis is
scarce, and conflicting. For example, Ruiz et al reported a substantial

OR CID

decrease in the percentage of patients who required blood transfusion
or erythropoietin injections after percutaneous PVL repair from 56%
55

to 5%.
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On the contrary, in another study of 168 patients with PVL,

blood transfusion requirements decreased only modestly after percu-

RE FE RE NCE S

taneous repair from 34% to 21%.79 These inconsistencies may be
related to the variable definitions of hemolysis and the degree of PVL
reduction achieved. Several studies have demonstrated that effective
correction of hemolysis in these patients requires complete amelioration of the PVL.16,17,55,64,66,80 Nonetheless, this can be challenging
due to various patients' and device-specific reasons. Indeed, up to
30% of patients undergoing percutaneous PVL repair have >mild
residual PVL following intervention even at centers of excellent.17,28,64,80 Among patients with significant residual leaks, a small
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